What is Arbutus Biopharma Corp (ABUS) stock price today?

Arbutus Biopharma Corp (ABUS) currently trades at $4.13 per share. The stock has a market capitalization of $813.36M and a P/E ratio of —x.

Is ABUS stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Arbutus Biopharma Corp has a Smart Value Score of 17/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Arbutus Biopharma Corp's revenue and earnings?

Arbutus Biopharma Corp has trailing twelve-month (TTM) revenue of $14.08M with profit margins of -237.90%. Earnings per share (EPS) is $-0.17.

Is ABUS stock overvalued or undervalued?

Based on our DCF model, Arbutus Biopharma Corp's intrinsic value is $5.13, representing a margin of safety of 18.91%. The stock currently trades at a P/E of —x.

ABUS

Arbutus Biopharma Corp

NASDAQ: ABUS · HEALTHCARE · BIOTECHNOLOGY

$4.13

-0.48% today

Updated 2026-04-29

Market cap

$813.36M

P/E ratio

—

P/S ratio

57.75x

EPS (TTM)

$-0.17

Dividend yield

—

52W range

$3 – $5

Volume

2.5M

Market cap

$813.36M

P/E ratio

—

P/S ratio

57.75x

EPS (TTM)

$-0.17

Dividend yield

—

52W range

$3 – $5

Volume

2.5M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

2.7

Growth

5.0

Quality

C+

2.0

Profitability

6.0

Valuation

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$5.22

+26.39%

12-Month target

—

Intrinsic (DCF)

$5.13

Margin of safety

+18.91%

1 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ 18.91% below intrinsic value

Risks

- Thin margins at -237.90%

- Negative free cash flow $-4.68M

- Revenue declining -33.20% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$39.02M	$18.14M	$6.17M	$14.08M	$14.08M
Net income	$-69.46M	$-72.85M	$-69.92M	$-33.50M	$-3.76M
EPS	—	—	—	—	$-0.17
Free cash flow	$-35.87M	$-86.94M	$-65.03M	$-39.64M	$-4.68M
Profit margin	-178.01%	-401.57%	-1,133.04%	-237.88%	-237.90%

Recent insider activity

Date	Insider	Type	Shares	Price
2026-02-02	NGUYEN, TUAN	Buy	188,400	—
2026-02-02	NGUYEN, TUAN	Buy	73,500	—
2026-02-02	ANDROSKI, LINDSAY	Buy	71,700	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
ABUS	$813.36M	17	2.7	2.0	6.0	5.0	+18.91%	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Arbutus Biopharma Corp trades at $4.13. Our Smart Value Score of 17/100 indicates the stock is weak. TTM revenue stands at $14.08M. with profit margins at -237.90%. Our DCF model estimates intrinsic value at $5.13.

Frequently asked questions

What is Arbutus Biopharma Corp's stock price?

Arbutus Biopharma Corp (ABUS) trades at $4.13.

Is Arbutus Biopharma Corp overvalued?

Smart Value Score 17/100 (Grade F, Strong Sell). DCF value $5.13.

What is the price target of Arbutus Biopharma Corp (ABUS)?

The analyst target price is $5.22, representing +26.4% upside from the current price of $4.13.

What is the intrinsic value of Arbutus Biopharma Corp (ABUS)?

Based on our DCF model, intrinsic value is $5.13, a +18.9% margin of safety versus $4.13.

What is Arbutus Biopharma Corp's revenue?

TTM revenue is $14.08M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio57.75x

ROE-38.50%

Beta0.74

50D MA$4.43

200D MA$4.24

Shares out0.20B

Float0.13B

Short ratio—

Avg volume2.5M

Performance

1 week-6.32%

1 month-3.49%

3 months+0.24%

YTD-13.72%

1 year—

3 years—

5 years—

Compare

ABUS vs LLY →ABUS vs JNJ →ABUS vs ABBV →Stock screener →